Biogen Inc. (BIIB)
| Market Cap | 24.67B |
| Revenue (ttm) | 10.07B |
| Net Income (ttm) | 1.61B |
| Shares Out | 146.70M |
| EPS (ttm) | 10.97 |
| PE Ratio | 15.32 |
| Forward PE | 13.22 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,914,503 |
| Open | 168.15 |
| Previous Close | 167.93 |
| Day's Range | 165.75 - 170.91 |
| 52-Week Range | 110.04 - 170.91 |
| Beta | 0.15 |
| Analysts | Buy |
| Price Target | 174.62 (+3.83%) |
| Earnings Date | Oct 30, 2025 |
About BIIB
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar r... [Read more]
Financial Performance
In 2024, Biogen's revenue was $9.68 billion, a decrease of -1.62% compared to the previous year's $9.84 billion. Earnings were $1.63 billion, an increase of 40.57%.
Financial StatementsAnalyst Summary
According to 23 analysts, the average rating for BIIB stock is "Buy." The 12-month stock price target is $174.62, which is an increase of 3.83% from the latest price.
News
Biogen to Highlight New Lecanemab Data and Scientific Advances at the 18th Clinical Trials on Alzheimer's Disease Conference
CAMBRIDGE, Mass., Nov. 20, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming scientific presentations at the 18th Clinical Trials on Alzheimer's Disease (CTAD) Conference, t...
Biogen and Stoke Therapeutics Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
– Despite treatment with standard-of-care anti-seizure medicines, children with Dravet syndrome experienced high seizure burden and plateaued in neurodevelopment, resulting in a widening gap relative ...
Stoke Therapeutics and Biogen Announce Publication of Two-Year Natural History Data Demonstrating the Severity of Dravet Syndrome, Including Frequent Seizures and Significant Cognitive and Behavioral Impairments
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
High Dose Regimen of Nusinersen Receives Positive CHMP Opinion for the Treatment of Spinal Muscular Atrophy
CAMBRIDGE, Mass., Nov. 17, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) adopted ...
Biogen Completes Acquisition of Alcyone Therapeutics
CAMBRIDGE, Mass., Nov. 14, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) has completed the acquisition of Alcyone Therapeutics, a clinical-stage biotechnology company known for its innovative CN...
Biogen Inc. (BIIB) Presents at TD Cowen Immunology and Inflammation Summit Transcript
Biogen Inc. ( BIIB) TD Cowen Immunology and Inflammation Summit November 13, 2025 4:30 PM EST Company Participants Diana Gallagher Conference Call Participants Philip Nadeau - TD Cowen, Research Divi...
“LEQEMBI®” (lecanemab) IV Maintenance Dosing for the Treatment of Early Alzheimer's Disease Approved in the United Kingdom
TOKYO and CAMBRIDGE, Mass., Nov. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massach...
Biogen Inc. (BIIB) Presents at Wedbush Rewind ASN 2025 Conference Prepared Remarks Transcript
Biogen Inc. ( BIIB) Wedbush Rewind ASN 2025 Conference November 10, 2025 1:20 PM EST Company Participants Uptal Patel - Chief Medical Officer Conference Call Participants Laura Chico - Wedbush Securi...
Biogen to Highlight Scientific Progress in Rare Kidney Disease at American Society of Nephrology (ASN) Kidney Week 2025
CAMBRIDGE, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) – will present new data from its felzartamab clinical development programs at Kidney Week 2025, the American Society of N...
Biogen Inc. (BIIB) Q3 2025 Earnings Call Transcript
Biogen Inc. ( BIIB) Q3 2025 Earnings Call October 30, 2025 8:30 AM EDT Company Participants Tim Power - Head of Investor Relations Christopher Viehbacher - President, CEO & Director Priya Singhal - E...
Biogen Cuts Full-Year Earnings Guidance, Despite Third-Quarter Profit Rise
Biogen cut its full-year adjusted-earnings expectations, though third-quarter profit rose on strength from its Alzheimer's drug and rare-disease treatments.
Biogen trims annual profit forecast on expected hit from R&D-related charges
Biogen cut its annual profit forecast on Thursday, as it expects to take a hit of $1.25 per share from R&D related charges tied to certain acquisitions in the fourth quarter.
Health Canada Grants Authorization for “LEQEMBI®” (lecanemab) for the Treatment of Early Alzheimer's Disease
In Canada, lecanemab is indicated for the treatment of adult patients with a clinical diagnosis of mild cognitive impairment or mild dementia due to Alzheimer's disease (early AD) who are apolipoprote...
Biogen licenses Vanqua Bio's immune disorder drug for up to $1.06 billion
Biogen said on Friday it has gained global rights to privately held Vanqua Bio's experimental drug for up to $1.06 billion to expand its pipeline of immunology drugs.
Biogen Licenses Oral C5aR1 Antagonist from Vanqua Bio to Expand Immunology Portfolio
CAMBRIDGE, Mass. and CHICAGO, Oct. 24, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) and Vanqua Bio today announced a license agreement granting Biogen exclusive worldwide rights to Vanqua's pr...
Biogen to Present Additional Results from Phase 3 Study of Dapirolizumab Pegol in Systemic Lupus Erythematosus at ACR Convergence 2025
CAMBRIDGE, Mass., Oct. 22, 2025 (GLOBE NEWSWIRE) -- Biogen Inc. (Nasdaq: BIIB) today announced upcoming presentations from studies evaluating dapirolizumab pegol (DZP), a novel Fc-free anti-CD40L drug...
LEQEMBI® IQLIK™(lecanemab-irmb) Subcutaneous Autoinjector Named to TIME's “Best Inventions of 2025”
TOKYO and CAMBRIDGE, Mass., Oct. 13, 2025 (GLOBE NEWSWIRE) -- Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Headquarters: Cambridge, Massachusetts, CE...
Biogen and Stoke Therapeutics Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
– An analysis designed to evaluate the potential effects of the Phase 3 zorevunersen dosing regimen showed continuing improvements in cognition and behavior at 2 years; results contrast with minimal c...
Stoke Therapeutics and Biogen Present New Data at the 54th Child Neurology Society (CNS) Annual Meeting that Support the Potential of Zorevunersen as a Disease-Modifying Medicine for Dravet Syndrome
BEDFORD, Mass., & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Stoke Therapeutics, Inc. (Nasdaq: STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with ...
Biogen's Comeback: Why The Bulls Are Finally Winning Again
Mr. Market's bullish sentiment towards Biogen is returning. One reason for this is its strengthening position in the multiple sclerosis drugs market, thanks to Vumerity, whose sales reached $212.3 mil...
Eisai and Biogen Announce U.S. Availability of LEQEMBI® IQLIK™ (lecanemab-irmb) Subcutaneous Injection Maintenance Dose for Treatment of Early Alzheimer's Disease
New LEQEMBI CompanionTM program launched to expand helpful resources for patients throughout the treatment journey, including Nurse Educators who can provide patients with injection training, and an i...
My Top 5 Biotech Stocks Big Pharma Could Buy Next
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of ...
BIIB Stock: Is Biogen Still A Buy After The 14% Spike?
Biogen (BIIB) shares recorded their fifth consecutive day of increases, accumulating a total return of 14% during this span. The company's market value has increased by approximately $3.3 billion over...
‘Fast Money' traders talk opportunities in health care stocks
The Fast Money traders discuss why health care stocks look attractive on valuations, how underweight positioning could drive sustainability, why recent White House policy moves may be a “gift” to phar...